Dicycloplatin is primarily used in cancer treatment as an antitumor agent. It demonstrates activity against various solid tumors, including testicular, ovarian, and lung cancers. The compound functions by binding to DNA and inducing cross-links, which disrupts DNA replication and transcription, ultimately leading to apoptosis in rapidly dividing cancer cells. Due to its unique structure, Dicycloplatin may offer reduced toxicity and improved efficacy compared to traditional platinum-based chemotherapeutics. It is under investigation in clinical trials to evaluate its therapeutic potential and safety profile in different cancer types.